Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Anatomic Outcomes Following Ozurdex Injections

This study has been completed.
Information provided by (Responsible Party):
Rhonda Weeks, Barnes Retina Institute Identifier:
First received: January 21, 2011
Last updated: July 26, 2016
Last verified: July 2016
Ozurdex(TM) has recently been FDA approved for use in macular edema secondary to retinal vein occlusion. It remains unclear how quickly the drug works and for how long as the initial studies did not have frequent anatomic monitoring. This study will utilize frequent Spectral domain OCT imaging to better understand the onset of treatment effectiveness and duration of action on the anatomic thickness of the retina, in addition to distinguishing structural abnormalities of responders from non-responders.

Retinal Vein Occlusions

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Anatomic Outcomes Following Ozurdex Injection

Further study details as provided by Barnes Retina Institute:

Enrollment: 10
Study Start Date: February 2010
Study Completion Date: July 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Detailed Description:
Focal laser therapy has been the gold standard for the treatment of macular edema secondary to branch vein occlusion (BRVO), though it has not been shown to be effective for central vein occlusion (CRVO). Intravitreal corticosteroids have been shown in many case series to be effective at diminishing macular edema secondary to both BRVO and CRVO. Sustained drug delivery models have been sought after to relieve the need for frequent injections. Ozurdex has recently been found to be effective for the treatment of macular edema following BRVO or CRVO and has been approved by the FDA for these indications. The onset of effectiveness and duration of action on the anatomic thickness of the retina have not yet been demonstrated. In addition, it is uncertain as to when the clinician can label the patient as a responder or nonresponder. We also believe this study will help identify patients that may need more frequent dosing schedules.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Branch retinal vein occlusion (BRVO) Central retinal Vein occlusion (CRVO)

Inclusion Criteria:

  • Patients diagnosed with BRVO/CRVO who are otherwise eligible to receive treatment with Ozurdex (TM)

Exclusion Criteria:

  • Patients younger than 21 years of age, unwilling or unable to grant informed consent, participation in a clinical trial within the 30 days prior to enrollment. Patients receiving any other ocular therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01282411

United States, Missouri
Barnes Retina Institute
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Barnes Retina Institute
Principal Investigator: Gaurav K Shah, MD Barnes Retina Institute
  More Information

Responsible Party: Rhonda Weeks, Gaurav K. Shah, MD, Barnes Retina Institute Identifier: NCT01282411     History of Changes
Other Study ID Numbers: 2010.006 
Study First Received: January 21, 2011
Last Updated: July 26, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Retinal Vein Occlusion
Retinal Diseases
Eye Diseases
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases processed this record on October 21, 2016